Figure 1. CD4⁺CD25^highFOXP3⁺ T cells and microvesicles (MV) in cancer patients and normal controls (NC).

(A) Percentages of CD4⁺CD25^highFOXP3⁺ Treg in PBMC of cancer patients and NC. (B) the protein content/10 mL of serum or ascites in cancer patients and NC. The data in A and B are mean values ± SD. (C) Flow analyses of IL-10, TGF-β1 and FasL expression in MV purified from the ascites of OvCa patients and coated on latex beads. (D) Western blots of TMV isolated from OvCa SN. Molecular weights of the detected proteins are indicated. (E) Percentages of CD4⁺CD25⁺FOXP3⁺ cells in 8-day co-cultures of CD4⁺CD25^neg T cells with TMV obtained from various sources and used at increasing concentrations. The asterisks indicate a significant increase at p<0.05.